-

06:54:31 AM

Latest CSLLY Stock Market News

CSLLY - CSL Ltd.

09/09/21 8:30 AM

OTC : CSLLY

management

Urban League of Philadelphia Names CSL's Elizabeth Walker to Board of Directors

CSL's Global Chief Human Resources Officer Elizabeth Walker has been appointed to the Urban League of Philadelphia's Board of Directors."I am honored to be part of this group," Walker said. "In providing life-saving medicines in

RHEA-AI

neutral

08/26/21 8:07 AM

OTC : CSLLY

CSL Plasma to Provide Flu Vaccines to U.S. Plasma Donors

CSL Plasma today announced it will provide influenza (flu) vaccination vouchers to U.S. plasma donors following the completion of two plasma donations made within a calendar month. Beginning Sept. 1, donors can redeem vouchers for the vaccine at no

RHEA-AI

negative

08/19/21 8:30 AM

OTC : CSLLY

Seqirus Announces Investment in Next-Generation Influenza Vaccine Technology, Self-Amplifying Messenger RNA (sa-mRNA)

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced plans to accelerate the development of its next generation of messenger RNA (mRNA) vaccine technology, self-amplifying messenger RNA (sa-mRNA), with

RHEA-AI

neutral

08/09/21 9:20 AM

OTC : CSLLY

The European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force Has Strongly Recommended Subcutaneous Immunoglobulin (SCIg) for CIDP Maintenance Treatment

Global biotherapeutics leader CSL Behring today announced that the European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force has released an update to its guideline on diagnosis and treatment of Chronic Inflammatory

RHEA-AI

neutral

08/03/21 9:10 AM

OTC : CSLLY

fda approval

FDA Approves New BERINERT® (C1 Esterase Inhibitor, Human (Intravenous)) Administration Kit for Increased Patient Convenience

CSL Behring, a global biotherapeutics leader received U.S. Food and Drug Administration (FDA) approval for its supplemental request (submitted Aug. 30, 2020) for co-packaging of a convenience administration kit along with its product BERINERT,

RHEA-AI

neutral

07/30/21 8:30 AM

OTC : CSLLY

Seqirus Presents New Safety Data Demonstrating Safety of Cell-Based Seasonal Influenza Vaccine on Pregnancy Outcomes

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), presented findings from a new observational safety study conducted in the U.S. that found no unexpected adverse pregnancy outcomes in pregnant people who were

RHEA-AI

neutral

07/27/21 8:30 AM

OTC : CSLLY

Seqirus Begins Shipping Portfolio of Innovative Vaccines for the 2021/22 U.S. Influenza Season

Seqirus offers a differentiated portfolio of influenza vaccines, including FLUCELVAX ® QUADRIVALENT (Influenza Vaccine), the first and only cell-based quadrivalent influenza vaccine for eligible persons two years of age and older; and FLUAD ® QUADRIVALENT

RHEA-AI

neutral

06/14/21 4:05 PM

OTC : CSLLY

covid-19

Seqirus Co-Authors First Study to Assess Simultaneous Administration of Seasonal Influenza Vaccine and COVID-19 Vaccine Candidate

Seqirus, a global leader in influenza prevention and a division of CSL Limited (ASX: CSL), today announced that the company co-authored the first study to demonstrate the safety, immunogenicity and efficacy profile of a COVID-19 vaccine when

RHEA-AI

neutral

06/08/21 9:00 AM

OTC : CSLLY

Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) To Be Covered Under Medicare Part B Effective July 18, Improving Access and Reducing Out-of-Pocket Costs for CIDP Patients

Global biotherapeutics leader CSL Behring today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Hizentra for coverage under Medicare Part B for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy

RHEA-AI

positive

05/16/21 1:15 PM

OTC : CSLLY

New Meta-Analysis of Patients with Acute Coronary Syndrome Shows Nearly Half of Recurrent Major Adverse Cardiovascular Events at One Year Occur Within the First 90 Days

Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that included more than 82,000 high-risk patients with recent acute coronary syndrome (ACS). The findings

RHEA-AI

neutral